224 related articles for article (PubMed ID: 35077729)
1. Age-related changes in CB1 receptor expression and function and the behavioral effects of cannabinoid receptor ligands.
Ginsburg BC; Hensler JG
Pharmacol Biochem Behav; 2022 Feb; 213():173339. PubMed ID: 35077729
[TBL] [Abstract][Full Text] [Related]
2. Sex, THC, and hormones: Effects on density and sensitivity of CB
Farquhar CE; Breivogel CS; Gamage TF; Gay EA; Thomas BF; Craft RM; Wiley JL
Drug Alcohol Depend; 2019 Jan; 194():20-27. PubMed ID: 30391834
[TBL] [Abstract][Full Text] [Related]
3. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison.
Ginsburg BC; Lamb RJ
Behav Pharmacol; 2006 May; 17(3):249-57. PubMed ID: 16572003
[TBL] [Abstract][Full Text] [Related]
6. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
7. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
8. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201.
AlKhelb D; Burke EL; Zvonok A; Iliopoulos-Tsoutsouvas C; Georgiadis MO; Jiang S; Ho TC; Nikas SP; Makriyannis A; Desai RI
Eur J Pharmacol; 2023 Dec; 960():176168. PubMed ID: 38059442
[TBL] [Abstract][Full Text] [Related]
9. JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.
Rodriguez JS; McMahon LR
Eur J Pharmacol; 2014 Oct; 740():151-9. PubMed ID: 24972243
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
11. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
[TBL] [Abstract][Full Text] [Related]
12. Δ
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2018 Mar; 235(3):673-680. PubMed ID: 29138877
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
14. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
15. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats.
Yamaguchi T; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Jan; 889(1-2):149-54. PubMed ID: 11166698
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.
Desai RI; Thakur GA; Vemuri VK; Bajaj S; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Feb; 344(2):319-28. PubMed ID: 23197773
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid-induced lower lip retraction in rats.
Chopda GR; Nikas SP; Sharma R; Kulkarni S; Makriyannis A; Paronis CA
Psychopharmacology (Berl); 2019 Apr; 236(4):1199-1206. PubMed ID: 30460515
[TBL] [Abstract][Full Text] [Related]
19. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Singh H; Schulze DR; McMahon LR
Psychopharmacology (Berl); 2011 Jun; 215(4):665-75. PubMed ID: 21246187
[TBL] [Abstract][Full Text] [Related]
20. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol.
Romero J; Berrendero F; Manzanares J; Pérez A; Corchero J; Fuentes JA; Fernández-Ruiz JJ; Ramos JA
Synapse; 1998 Nov; 30(3):298-308. PubMed ID: 9776133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
